Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer (EMUNE-07)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Cook
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00548626
First received: October 22, 2007
Last updated: September 6, 2013
Last verified: June 2013

October 22, 2007
September 6, 2013
October 2007
September 2014   (final data collection date for primary outcome measure)
Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia. [ Time Frame: October 2007- September 2008 ] [ Designated as safety issue: No ]
Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.
Complete list of historical versions of study NCT00548626 on ClinicalTrials.gov Archive Site
  • Rate of complications related with EUS-FNA [ Time Frame: October 2007- September 2008 ] [ Designated as safety issue: Yes ]
  • Influence of different factors in obtaining a positive cytological result [ Time Frame: October 2007- September 2008 ] [ Designated as safety issue: No ]
  • Rate of complications related with EUS-FNA
  • Influence of different factors in obtaining a positive cytological result
Not Provided
Not Provided
 
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
EMUNE-07 Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer

The aim of this study is to evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer allows an earlier preliminary cytological diagnosis of neoplasia.

This is a prospective randomized controlled trial which will recruit patients referred for suspicion of pancreatic mass and indication of EUS-FNA as part of standard of care in the Interventional Endoscopy Unit at the University Of Chicago Medical Center. Basic demographic data will be recorded for each patient. If a pancreatic mass is confirmed in EUS evaluation the patient will be randomized in a 1:1 ratio to either Control group (Single needle) or Investigational group (Multiple Needle). There will be an expert cytopathologist in the exploration room (blinded to the group assignment). Samples obtained through FNA will be prepared onsite either for cytological evaluation by the cytopathologist: each fine needle sample will be expressed by using a 10mL air-filled syringe onto a separate glass slide, and a direct smear will be made by an on-site cytopathologist. Each slide will be air-dried and/or alcohol fixed (95% ethanol), and direct smears will be prepared for immediate interpretation by staining with Diff-quick staining system.

Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.

Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.

A cytopathologist (#1) will be present during each EUS-FNA procedure to prepare the slides and determine whether each specimen was adequately cellular. After the procedure, all the cytological samples will be sent to the Pathology department in order to complete the study. A cytopathologist (#2) not present during the procedure will study all the sampling specimens obtained during the EUS-FNA procedure and produce the final and definitive cytopathological diagnosis.

Criteria for pancreatic cancer and benign pancreatic lesions will be defined. Follow-up of all patients to assess early and late complications will be carried out for 30 days after the procedure.

Endpoints:

  1. Primary endpoint: Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia. We hypothesized that the number of passes needed using the multiple needles will be significantly less than that using the single needle.
  2. Secondary endpoints:

    • Rate of complications related with EUS-FNA
    • Influence of different factors in obtaining a positive cytological result (histological differentiation)
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Diagnostic
Pancreatic Cancer
  • Procedure: Single needle
    Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
  • Procedure: Multiple needle
    Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
  • Active Comparator: A
    Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
    Intervention: Procedure: Single needle
  • Experimental: B
    Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
    Intervention: Procedure: Multiple needle

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
November 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suspicion of pancreatic mass due to previous exam/s (CT, MR, ERCP, US, …) that requires EUS-FNA in order to complete diagnosis
  • Age ≥ 18 y/o
  • Formal informed consent
  • No previous chemotherapy or radiotherapy
  • No previous pancreatic surgery

Exclusion Criteria:

  • Any patient unable to understand the procedure, nature of the current study, or sign a consent form.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00548626
15497A
No
University of Chicago
University of Chicago
Cook
Principal Investigator: Irving Waxman, MD Department of Medicine, University of Chicago Medical Center
University of Chicago
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP